Predictive biomarkers and personalized medicine molecular determinants of retinoic acid sensitivity in pancreatic cancer

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 280-289

  Gupta, Sonal ^a   Pramanik, Dipankar ^a   Mukherjee, Radha ^a   Campbell, Nathaniel R ^a   Elumalai, Sathyanarayanan ^a   De Wilde, Roeland F ^a   Hong, Seung Mo ^a,b   Goggins, Michael G ^a   De Jesus Acosta, Ana ^a   Laheru, Daniel ^a   Maitra, Anirban ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELLULAR RETINOIC ACID BINDING PROTEIN 2; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 5; GEMCITABINE; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FABP5 PROTEIN, HUMAN; MESSENGER RNA; RETINOIC ACID BINDING PROTEIN II, CELLULAR; RETINOIC ACID RECEPTOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL ADHESION; CELL MOTION; DNA METHYLATION; DNA MICROARRAY; DRUG EFFECT; ENZYME IMMUNOASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84855442208     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2165     Document Type: Article

References (28)

1. Altekruse SF, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, et al., editors. SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010.
2. Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 2010;3:111-27.
3. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93. (Pubitemid 33741893)
4. El-Metwally TH, Hussein MR, Pour PM, Kuszynski CA, Adrian TE. High concentrations of retinoids induce differentiation and late apoptosis in pancreatic cancer cells in vitro. Cancer Biol Ther 2005;4:602-11. (Pubitemid 41351237)
5. Nakagawa T, Shimizu M, Shirakami Y, Tatebe H, Yasuda I, Tsurumi H, et al. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett 2009;273:250-6.
6. Albrechtsson E, Ohlsson B, Axelson J. The expression of retinoic acid receptors and the effects in vitro by retinoids in human pancreatic cancer cell lines. Pancreas 2002;25:49-56. (Pubitemid 34760836)
7. Leelawat K, Ohuchida K, Mizumoto K, Mahidol C, Tanaka M. All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett 2005;224:303-10. (Pubitemid 40725850)
8. Michael A, Hill M, Maraveyas A, Dalgleish A, Lofts F. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer-report of a pilot phase II study. Clin Oncol (R Coll Radiol) 2007;19:150-3. (Pubitemid 46172839)
9. Moore DF Jr, Pazdur R, Sugarman S, Jones D III, Lippman SM, Bready B, et al. Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. Am J Clin Oncol 1995;18:525-7.
10. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007;129:723-33.
11. Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci U S A 2008;105:7546-51.
12. Shaw N, Elholm M, Noy N. Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. J Biol Chem 2003;278:41589-92. (Pubitemid 37310413)
13. Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine wnt-beta-catenin signaling to slow tumor progression. Gastroenterology 2011;141:1486-97.
14. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
15. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G. Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 2002;265:39-47. (Pubitemid 34628803)
16. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-96. (Pubitemid 46424238)
17. el-Metwally TH, Hussein MR, Pour PM, Kuszynski CA, Adrian TE. Natural retinoids inhibit proliferation and induce apoptosis in pancreatic cancer cells previously reported to be retinoid resistant. Cancer Biol Ther 2005;4:474-83. (Pubitemid 41351268)
18. Morgan E, Kannan-Thulasiraman P, Noy N. Involvement of fatty acid binding protein 5 and PPARbeta/delta in prostate cancer cell growth. PPAR Res 2010;2010.pii: 234629.
19. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-9. (Pubitemid 26374508)
20. Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J, Goggins M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res 2011;17:4341-54.
21. VirmaniAK, Rathi A, Zochbauer-Muller S,Sacchi N, Fukuyama Y, Bryant D, et al. Promotermethylation and silencing of the retinoic acid receptorbeta gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-7. (Pubitemid 30660589)
22. Dong D, Ruuska SE, Levinthal DJ, Noy N. Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid. J Biol Chem 1999;274:23695-8.
23. Tan NS, Shaw NS, Vinckenbosch N, Liu P, Yasmin R, Desvergne B, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 2002;22:5114-27. (Pubitemid 34700702)
24. Sussman F, de Lera AR. Ligand recognition by RAR and RXR receptors: binding and selectivity. J Med Chem 2005;48:6212-9. (Pubitemid 41428976)
25. Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia 2009;11:1329-39.
26. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005;11:4681-8. (Pubitemid 41557185)
27. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, AlbitarM, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803.
28. David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM. Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Ther 2010;9:678-84. 29. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, et al. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 2005;11:3558-66. (Pubitemid 40627912)